Tumor cells with different HLA typing can be artificially modified with relative HLA‐restricted peptides and be recognized by specific TCR‐T cells, since there are several TCR‐T products (such as MAGE‐A4 TCR‐T and MSLN TCR‐T) that have entered clinical trial. This evidence concerns the gene MSLN and neoplasm.